Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

Trial ID or NCT#



not recruiting iconNOT RECRUITING


This clinical study will evaluate whether taking an investigational drug called exendin 9-39 is safe, well-tolerated, and helps to prevent low blood sugar in people who have had bariatric surgery and later develop a rare condition called postbariatric hypoglycemia (PBH).

Official Title

A Phase 2, Multicenter, Randomized, Single-Blind, Placebo-Controlled Cross-over Study to Assess the Efficacy and Safety of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

Eligibility Criteria

Ages Eligible for Study: 18 Years to 65 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Body mass index (BMI) of up to 40 kg/m2* Roux-en-Y gastric bypass (RYGB) surgery performed ≥12 months prior* Diagnosis of PBH* At least 2 episodes during screening 2-week run-in phase of severe hypoglycemia
Exclusion Criteria:
  1. * Other cause of endogenous hyperinsulinism other than PBH* Metabolic or bariatric surgical procedure other than RYGB* History of non-RYGB upper GI surgery* Use of agents that may interfere with glucose metabolism


Marilyn Tan
Marilyn Tan
Clinical Associate Professor, Medicine - Endocrinology, Gerontology, & Metabolism

Contact us to find out if this trial is right for you.


Aileen Muno
(650) 725-9890